IGF-BP7, human recombinant | 7167

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

7167 | IGF-BP7 human recombinant DataSheet

Biomolecule/Target: IGF-BP7

Synonyms: Insulin-like growth factor binding protein-7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBPrP1)

Alternates names: Superoxide dismutase [Mn], mitochondrial, IPOB, MNSOD, MVCD6.

Taglines: Plays a role in skeletal myogenesis by binding to IGF

NCBI Gene ID #: 6648

NCBI Gene Symbol: SOD2

Gene Source: Human

Accession #: P04179

Recombinant: Yes

Source: E. Coli

Purity by SDS-PAGEs: 95%

Assay: SDS-PAGE

Purity: N/A

Assay #2: HPLC

Endotoxin Level: < 0.1 ng/g of protein (<1EU/g).

Activity (Specifications/test method): N/A

Biological activity: Specific activity is > 1,200 units/mg

Results: >1,200 units/mg

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 24.4 kDa (219 aa, 25-222 aa + His Tag)

Concentration: N/A

Appearance: Lyophilized powder

Physical form description: Sterile filtered through a 0.2 micron filter. Lyophilized from 10 mM Acetic Acid

Reconstitution Instructions: N/A

Amino acid sequence: MGSSHHHHHH SSGLVPRGSH MKHSLPDLPY DYGALEPHIN AQIMQLHHSK HHAAYVNNLN VTEEKYQEAL AKGDVTAQIA LQPALKFNGG GHINHSIFWT NLSPNGGGEP KGelLEAIKR DFGSFDKFKE KLTAASVGVQ GSGWGWLGFN KERGHLQIAA CPNQDPLQGT TGLIPLLGID VWEHAYYLQY KNVRPDYLKA IWNVINWENV TERYMACKK